【作者】 王雅锋；

【导师】 方秋娟；

【作者基本信息】 福建医科大学 ， 生理学， 2007， 硕士

【摘要】 第一部分“钾维普”停搏液保护未成熟缺血心肌的适宜剂量目的观察含不同剂量维拉帕米、普奈洛尔的“钾维普”停搏液保护未成熟缺血心肌的效应,探讨其适宜剂量。方法幼大鼠离体心脏Langendorff法灌流,37℃“钾维普”停搏液灌3min停灌27min、连续3阵（共缺血90min）,再灌注60min,建立缺血-再灌注损伤“钾维普”停搏液常温保护实验模型。实验分3组,“钾维普”停搏液中维拉帕米、普奈洛尔浓度（mol/L）分别为2.0×10^-6、3.4×10^-7;6.8×10^-7、1.1×10^-7;2.0×10^-7、3.4×10^-8。实验过程检测心率、心脏张力、收缩力、最大收缩速度和最大舒张速度、冠脉流量、复搏时间。结果中剂量组“钾维普”停搏液保护的未成熟心肌缺血期间张力低,再灌注后复搏好。结论含维拉帕米6.8×10^-7 mol/L、普奈洛尔1.1×10^-7mol/L的“钾维普”停搏液保护未成熟缺血心肌较佳。第二部分“钾维普”停搏液保护未成熟缺血心肌的效应目的评价“钾维普”停搏液对未成熟缺血心肌的保护效应,并与ST.Thomas’II停搏液比较。方法幼大鼠离体心脏Langendorff法37℃灌流,实验分正常灌注组,连续正常灌流170min;稳定灌流20min后,缺血再灌注组、ST.Thomas组、“钾维普”组缺血期分别用无糖不充氧洛氏液、ST.Thomas’II停搏液、含维拉帕米、普奈洛尔分别为6.8×10^-7、1.1×10^-7（mol/L）的“钾维普”停搏液灌3min停灌27min重复3次（共缺血90min）,再灌注60min。实验中动态检测心功能变化;实验结束取心肌组织测Na+-K+ ATP酶、超氧化物歧化酶、丙二醛,并观察心肌组织学及超微结构变化。结果含有维拉帕米6.8×10^-7 mol/L、普奈洛尔1.1×10^-7mol/L的“钾维普”停搏液降低了未成熟缺血心肌的张力,但没有延迟再灌注心脏复搏;增强了未成熟缺血再灌注心肌的舒缩功能,改善了冠脉流量;避免了能量消耗,增强了抗氧化特性;保证了心肌组织及线粒体的完整。结论含适宜剂量维拉帕米、普奈洛尔的“钾维普”停搏液常温保护未成熟缺血心肌的效果优于高钾停搏液。更多还原

【Abstract】 The First Part The Appropriate Dose of“KVP”Cardioplegic Solution protecting Immature Ischemic MyocaidiumObjective To observe the protective effects of“KVP”cardioplegic solution including verapamil and propanolol of different doses and approach their appropriate doses. Methords The Langendorff- perfused isolated rat hearts, 37℃“KVP”cardioplegic solution arrested for 3min and then undergone ischemia for 27min（×3,90min） and reperfusion for 60min,were used for the models of ischemia-reperfusion injury“KVP”cardioplegic solution common temperature protection. The concentration（mol/L） of verapamil and propanolol were 2.0×10^-6,3.4×10^-7;6.8×10^-7,1.1×10^-7;2.0×10^-7,3.4×10^-8.We observed functional indexes including heart rate, tension, contraction force, peak systolic velocity, peak diastole velocity, coronary flow. Results Tension of the hearts was the lowest during ischemia and the beat of the hearts was best during reperfusion in middle dose group. Conclusions“KVP”cardioplegic solution including verapamil 6.8×10^-7mol/L, propanolol,1.1×10^-7mol/L was appropriate for immature myocardium.The Second Part The Effect of“KVP”Cardioplegic Solution on Immature Ischemic MyocaidiumObjective To evaluate the effect of“KVP”cardioplegic solution on immature ischemic myocaidium and compare it with ST.Thomas’II cardioplegic solution. Methords The 37℃Langendorff- perfused isolated rat hearts were divided into normal perfusion group（perfused for 170min consecutively）, ischemia/reperfusion group, ST.Thomas group,“KVP”group（during ischemia, respectively perfused with Locke’solution without oxygen and glucose, ST.Thomas’II cardioplegic solution,“KVP”cardioplegic solution for 3min,reperfusion for 60min）.We observed functional indexes. After the experiments, the hearts were used to measure biochemical indexes included Na+-K+ ATPase ,superoxide dismutase, malondialdehyde; observe myocardial histopathology and ultralstructure. Results“KVP”cardioplegic solution including appropriate dose of verapamil6.8×10^-7 mol/L, propanolol 1.1×10^-7mol/L attenuated immature ischemic myocardial tension,did not delay beating of heart,enhanced coronary flow;avoided energy consumption,enhanced antioxigy ;ensured myocardial integrality. Conclusions“KVP”cardioplegic solution including appropriate dose of verapamil and propanolol possessed better protective effects on immature ischemic myocardium than ST.Thomas’II cardioplegic solution.更多还原